Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 628 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Cancer in My Community: Accessing Care Through the Public Health System... May 9, 2023 EMA Recommends Granting a Marketing Authorisation for Duvelisib April 9, 2021 PDX Mouse Models Are Reliable Stand-Ins for Human Tumors, Study Finds February 2, 2021 FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC February 5, 2021 Load more HOT NEWS Median Survival Times for Two Forms of Advanced Breast Cancer Have... EMA Recommends Extension of Indications for Blinatumomab Lawmaker Dad Raises Awareness For RSV, An Illness He’d Never Heard... Addressing Cancer Pain with Complementary Methods (Part 2)
